Latest Advances

  • Condition: B-cell Malignancies, Mantle cell lymphoma, and Multiple Myeloma
  • Journal: Frontiers in immunology
  • Treatment Used: CAR T-Cell Therapy
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T-cell therapy in the treatment of patients with B-cell malignancies, mantle cell lymphoma, and multiple myeloma.
  • Condition: Mantle Cell Lymphoma
  • Journal: The Permanente journal
  • Treatment Used: Concurrent Radiotherapy and Lenalidomide
  • Number of Patients: 1
  • Published —
In this study, researchers evaluated the safety and effectiveness of adding lenalidomide to radiotherapy for the treatment of mantle cell lymphoma.
  • Condition: Mantle Cell Lymphoma
  • Journal: Current oncology (Toronto, Ont.)
  • Treatment Used: Rituximab
  • Number of Patients: NULL
  • Published —
The study researched the outcomes of treatment for mantle cell lymphoma.
  • Condition: Mantle Cell Lymphoma
  • Journal: The Lancet. Haematology
  • Treatment Used: Lenalidomide Maintenance After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
  • Number of Patients: 303
  • Published —
This study investigated whether lenalidomide maintenance improves progression-free survival after autologous hematopoietic stem cell transplantation (replacement of a recipient’s bone marrow with donor hematopoietic stem cells; HSCT) in patients with mantle cell lymphoma (cancer of white blood cells).
  • Condition: Mantle Cell Lymphoma
  • Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
  • Treatment Used: Ibrutinib
  • Number of Patients: 1
  • Published —
The study researched a case of mantle cell lymphoma.
  • Condition: Relapsed/Refractory Mantle Cell Lymphoma
  • Journal: Drugs of today (Barcelona, Spain : 1998)
  • Treatment Used: Zanubrutinib
  • Number of Patients: 118
  • Published —
The study researched the outcomes of Zanubrutinib for treating relapsed/refractory mantle cell lymphoma.
  • Condition: Mantle Cell Lymphoma
  • Journal: Blood advances
  • Treatment Used: Bendamustine and Rituximab as Induction Therapy
  • Number of Patients: 190
  • Published —
In this study, researchers evaluated the outcomes of using bendamustine and rituximab as induction therapy for the treatment of mantle cell lymphoma.
  • Condition: Spontaneous Tumor Lysis Syndrome (SPTLS) in Blastoid-Variant Mantle Cell Lymphoma
  • Journal: Journal of investigative medicine high impact case reports
  • Treatment Used: Rasburicase
  • Number of Patients: 1
  • Published —
This case report describes a patient with blastoid-variant mantle cell lymphoma diagnosed with spontaneous tumor lysis syndrome (SPTLS).
  • Condition: Relapse and Refractory Mantle Cell Lymphoma
  • Journal: Annals of hematology
  • Treatment Used: Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens
  • Number of Patients: 41
  • Published —
This study investigated the recommended dose of temsirolimus in association with R-CHOP (R-CHOP-T), or high-dose cytarabine plus rituximab (R-DHA-T), or fludarabine, cyclophosphamide plus rituximab (R-FC-T) in patients with relapse and refractory mantle cell lymphoma.
  • Condition: Mantle Cell Lymphoma
  • Journal: Terapevticheskii arkhiv
  • Treatment Used: Adapted Intensive Induction Therapy, Autologous Stem Cell Transplantation, and Rituximab
  • Number of Patients: 47
  • Published —
The study researched the outcomes of adapted intensive induction therapy, autologous stem cell transplantation, and rituximab for treating mantle cell lymphoma.
  • Condition: Mantle Cell Lymphoma
  • Journal: Cancer cell
  • Treatment Used: CAR T Cells
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T cells for the treatment of patients with mantle cell lymphoma.
  • Condition: Relapsed or Refractory Mantle-Cell Lymphoma (MCL)
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Zanubrutinib
  • Number of Patients: 86
  • Published —
This study evaluated the safety and effectiveness of zanubrutinib in patients with relapsed or refractory mantle-cell lymphoma (MCL).
Showing 1-12 of 77